Vaccine Analysis: Strategies, Principles, and Control

  title={Vaccine Analysis: Strategies, Principles, and Control},
  author={Brian K. Nunnally and Vincent E. Turula and Robert D. Sitrin},
  booktitle={Springer Berlin Heidelberg},

Figures and Tables from this paper

Enhancing the Immunogenicity of Whole Inactivated H9N2 Influenza Virus Vaccines in Chickens
This research presented at the 2015 Canadian Poultry Research Council conference focused on the development of novel and sustainable alternatives to conventional brooding techniques for brooding chickens. Expand
Edwardsiella tarda outer membrane protein 1 is a virulence factor and a protective immunogen
Results indicate that Omp1Et is a surface-located virulence factor of E. tarda and rOmp 1Et can induce effective immune-protection as a submit vaccine. Expand
Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development
The potential use of γ-irradiation to inactivate this virus by damaging at the molecular level its genetic material is analyzed and is a vital step towards the design and development of an urgently needed, effective vaccine against this disease. Expand
Global acceptance and hesitancy of COVID-19 vaccination: A narrative review
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major global health threat to human civilization and has disrupted manyExpand
Glycoconjugate Vaccines for Prevention of Haemophilus influenzae Type b Diseases
Abstract This review summarizes the experience in laboratory- and industrial-scale syntheses of glycoconjugate vaccines used for prevention of infectious diseases caused by Haemophilus influenzaeExpand
Immunogenicity and Safety Analysis of Inactivated Virus Vaccine against SARS-CoV-2: A Systematic Review of Phase 1/2 Clinical Trials
The inactivated vaccine’s efficacy has been proven to stimulate antibody response regardless of dosage, period of administration, and age, with insignificant adverse effects. Expand
Recent advances on smart glycoconjugate vaccines in infections and cancer.
The latest advancements in development of vaccines against glycan epitopes to gain selective immune responses are discussed, and an overview on the role of different immunogenic constructs in improving glycovaccine efficacy is provided. Expand
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
The emergency use authorization by the US-FDA for two mRNA-based vaccines BNT162b2 and mRNA-1273 has brought hope of addressing the COVID-19 pandemic and demonstrates the potential utility of nanomedicine for tackling health problems at the global level. Expand
Should the world collaborate imminently to develop neglected live‐attenuated vaccines for COVID‐19?
Together, extensive global collaboration is imminently needed, which can greatly accelerate the development of safe COVID‐19 LAVs, which could save millions of more lives. Expand


Deep Sequencing Applications for Vaccine Development and Safety
The introduction of deep sequencing or massively parallel sequencing (MPS) technologies has resulted in a qualitative, as well as a quantitative, change in the information that can be gained fromExpand
Live Attenuated Viral Vaccines
The history of vaccination using live viruses extends through several centuries and is directly intertwined with the elimination of smallpox (variola major, Plotkin and Plotkin 2004). The wordExpand
Recombinant Virus-like Particle Protein Vaccines
Viral diseases offer a major challenge to vaccine development because of the complex nature of virus structures and the large size of the virus particle needed to generate an effective immuneExpand
Vaccines in Research and Development: New Production Platforms and New Biomolecular Entities for New Needs
Currently licensed vaccines have emanated from a relatively small number of production platforms. As shown in Table 9.1, these platforms have produced a large number of licensed products and areExpand
Virus-like particle-based human vaccines: quality assessment based on structural and functional properties.
How the crucial quality attributes of VLP-based human vaccines against all three disease indications were assessed, controlled, and improved during bioprocessing through an array of structural and functional analyses is reviewed. Expand
Pox: An American History
The development of vaccines: how the past led to the future
The history of vaccine development has seen many accomplishments, but there are still many diseases that are difficult to target, and new technologies are being brought to bear on them. PastExpand
The pharmaceutical industry in the twentieth century: A reappraisal of the sources of innovation
Abstract The authors use an historical case‐study of a single line of therapeutic development (in vaccines and serum antitoxins) to bring out salient aspects of the shifting sources of innovation inExpand
Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
Preface 1. 1894: 'The foremost medical question of the day' 2. The Mulford story 3. A Sharp & Dohme interlude 4. The virology network and a new programme at Merck, Sharp & Dohme 5. Hilleman'sExpand